Posted by Michael Wonder on 11 Nov 2019
NICE U-turn for Epidyolex in epilepsy
11 November 2019 - GW Pharma has announced that NICE has recommended Epidyolex (cannabidiol) for two rare, severe forms of childhood-onset epilepsy.
Initially the organisation rejected the cannabinoid prescription medicine due to the “evidence presented to it”, but promised that it would “work with the company to resolve the economic modelling issues identified by the committee, and to help them understand what they may need to do to mitigate the cost of cannabidiol to the NHS.”
The recommendation is for the drug in combination with clobazam, intended to treat Lennox Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.
